| SEC Form 4 |  |
|------------|--|
|------------|--|

I

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

| 1. Name and Address of Reporting Person <sup>*</sup><br><u>Price Ben Gil</u>     |               |                       | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br>AVI BIOPHARMA INC [ AVII ] |                        | tionship of Reporting Pe<br>all applicable)<br>Director                               | erson(s) to Issuer<br>10% Owner |  |  |  |  |
|--|---------------|-----------------------|--|------------------------|---|---------------------------------|--|--|--|--|
| (Last)<br>4575 SW RESE   | (First)       | (Middle)<br>SUITE 200 | 3. Date of Earliest Transaction (Month/Day/Year)<br>05/13/2010                   |                        | Officer (give title below)  | Other (specify below)           |  |  |  |  |
| (Street)<br>CORVALLIS<br>(City)  | OR<br>(State) | 97333<br>(Zip)        | 4. If Amendment, Date of Original Filed (Month/Day/Year)                         | 6. Indiv<br>Line)<br>X | idual or Joint/Group Fili<br>Form filed by One Re<br>Form filed by More the<br>Person | porting Person                  |  |  |  |  |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |               |                       |  |                        |   |                                 |  |  |  |  |

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Code ( |   | 4. Securities A<br>Disposed Of (<br>5) |               | 3, 4 and             | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|--------|---|--|---------------|----------------------|---|---|---|
|                                 |  |   | Code   | v | Amount                                 | (A) or<br>(D) | Price                | Transaction(s)<br>(Instr. 3 and 4)  |   | (1130.4)  |
| Common Stock                    | 05/13/2010                                 |   | Р      |   | 40,000                                 | Α             | \$1. <mark>36</mark> | 126,982   | D   |   |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)       | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | n of |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|------|-----|--|--------------------|---|--|---|--|--|--|
|   |   |  |   | Code                         | v | (A)  | (D) | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Non-<br>Qualified<br>Stock<br>Option<br>(right to<br>buy) | \$1.1   |  |   |                              |   |      |     | 05/19/2010 <sup>(1)</sup>                                      | 05/19/2019         | Common<br>Stock   | 20,000                                 |   | 20,000   | D  |  |
| Non-<br>Qualified<br>Stock<br>Option<br>(right to<br>buy) | \$1.55  |  |   |                              |   |      |     | 06/20/2008 <sup>(2)</sup>                                      | 05/20/2018         | Common<br>Stock   | 20,000                                 |   | 20,000   | D  |  |
| Non-<br>Qualified<br>Stock<br>Option<br>(right to<br>buy) | \$2.83  |  |   |                              |   |      |     | 10/29/2007 <sup>(1)</sup>                                      | 10/29/2017         | Common<br>Stock   | 33,000                                 |   | 33,000   | D  |  |

Explanation of Responses:

1. Vesting: 25% of the shares vest each year from the date of grant with all shares vesting in four years.

2. Option Grant vests monthly until all shares are vested one year from date of grant.

## Ben Gil Price, MD

05/13/2010

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.